Nodus Oncology

Nodus Oncology is a preclinical-stage biotechnology company developing small molecule inhibitors against novel DNA damage response targets for molecularly defined cancer patient populations.

The company's pipeline is focused on synthetic lethality and collateral vulnerabilities in tumours with specific DNA repair deficiencies.

Lead programmes include a best-in-class PARG inhibitor and a first-in-class DNA replication inhibitor targeting replication stress.

Nodus was founded by Cumulus Oncology and operates in partnership with the Lead Discovery Center in Dortmund.